Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

Launched by SHANGHAI CHEST HOSPITAL · Jan 18, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on studying a type of lung cancer called non-small-cell lung cancer (NSCLC), specifically looking at patients who have rare genetic mutations. These mutations can affect how the cancer behaves and how it responds to treatments. The goal of the study is to better understand these rare mutations and to help develop new, more effective treatments for patients with NSCLC.

To participate in this trial, individuals must be 18 years or older and have a confirmed diagnosis of NSCLC with specific rare mutations, such as those involving genes like EGFR or ROS1. There are no additional exclusion criteria, which means anyone meeting the inclusion criteria can join. Participants can expect to provide information about their condition, and their genetic data will be used to help researchers create a registry that could lead to personalized treatment options for NSCLC patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven diagnosis of NSCLC with rare mutations including EGFR rare mutations, ALK fusion, ROS1 fusion, BRAF V600E, cMET exon 14 skipping, KRAS G12C, RET fusion, NTRK fusion, etc.
• • 18 years of age or older
• • Ability to understand and the willingness to sign a written informed consent document
• Exclusion Criteria:
• • None